» Articles » PMID: 35513575

Comparative Characterization of 3D Chromatin Organization in Triple-negative Breast Cancers

Overview
Journal Exp Mol Med
Date 2022 May 5
PMID 35513575
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) is a malignant cancer subtype with a high risk of recurrence and an aggressive phenotype compared to other breast cancer subtypes. Although many breast cancer studies conducted to date have investigated genetic variations and differential target gene expression, how 3D chromatin architectures are reorganized in TNBC has been poorly elucidated. Here, using in situ Hi-C technology, we characterized the 3D chromatin organization in cells representing five distinct subtypes of breast cancer (including TNBC) compared to that in normal cells. We found that the global and local 3D architectures were severely disrupted in breast cancer. TNBC cell lines (especially BT549 cells) showed the most dramatic changes relative to normal cells. Importantly, we detected CTCF-dependent TNBC-susceptible losses/gains of 3D chromatin organization and found that these changes were strongly associated with perturbed chromatin accessibility and transcriptional dysregulation. In TNBC tissue, 3D chromatin disorganization was also observed relative to the 3D chromatin organization in normal tissues. We observed that the perturbed local 3D architectures found in TNBC cells were partially conserved in TNBC tissues. Finally, we discovered distinct tissue-specific chromatin loops by comparing normal and TNBC tissues. In this study, we elucidated the characteristics of the 3D chromatin organization in breast cancer relative to normal cells/tissues at multiple scales and identified associations between disrupted structures and various epigenetic features and transcriptomes. Collectively, our findings reveal important 3D chromatin structural features for future diagnostic and therapeutic studies of TNBC.

Citing Articles

Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling.

Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B Cell Genom. 2025; 5(2):100765.

PMID: 39914387 PMC: 11872555. DOI: 10.1016/j.xgen.2025.100765.


Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application.

Chen Y, Liang R, Li Y, Jiang L, Ma D, Luo Q Signal Transduct Target Ther. 2024; 9(1):340.

PMID: 39627201 PMC: 11615378. DOI: 10.1038/s41392-024-02030-9.


Secondary Transcriptomic Analysis of Triple-Negative Breast Cancer Reveals Reliable Universal and Subtype-Specific Mechanistic Markers.

Rapier-Sharman N, Spendlove M, Poulsen J, Appel A, Wiscovitch-Russo R, Vashee S Cancers (Basel). 2024; 16(19).

PMID: 39409999 PMC: 11476281. DOI: 10.3390/cancers16193379.


Deciphering MOSPD1's impact on breast cancer progression and therapeutic response.

Jiang Y, Li H, Wu S, Jiang B, Zeng L, Tang Y Biol Direct. 2024; 19(1):88.

PMID: 39369222 PMC: 11453086. DOI: 10.1186/s13062-024-00531-9.


Obtention of viable cell suspensions from breast cancer tumor biopsies for 3D chromatin conformation and single-cell transcriptome analysis.

Stephenson-Gussinye A, Rendon-Bautista L, Ruiz-Medina B, Blanco-Olais E, Perez-Molina R, Marcial-Medina C Front Mol Biosci. 2024; 11:1420308.

PMID: 39239354 PMC: 11375512. DOI: 10.3389/fmolb.2024.1420308.


References
1.
Esteller M . Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007; 8(4):286-98. DOI: 10.1038/nrg2005. View

2.
Shah S, Roth A, Goya R, Oloumi A, Ha G, Zhao Y . The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486(7403):395-9. PMC: 3863681. DOI: 10.1038/nature10933. View

3.
Zeitz M, Ay F, Heidmann J, Lerner P, Noble W, Steelman B . Genomic interaction profiles in breast cancer reveal altered chromatin architecture. PLoS One. 2013; 8(9):e73974. PMC: 3760796. DOI: 10.1371/journal.pone.0073974. View

4.
Dai X, Cheng H, Bai Z, Li J . Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16):3131-3141. PMC: 5665029. DOI: 10.7150/jca.18457. View

5.
Kumar P, Aggarwal R . An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2015; 293(2):247-69. DOI: 10.1007/s00404-015-3859-y. View